Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• BRAF fusions are identified in various cancers, but their treatment strategies are not well-defined.
• Understanding the molecular mechanisms behind BRAF fusion-driven tumorigenesis is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the differential responses of BRAF fusion-positive melanoma cell lines to RAF and MEK inhibitors.
• To elucidate the specific features of BRAF fusion kinases that dictate drug sensitivity or resistance.
• To evaluate the efficacy of next-generation RAF inhibitors in combination with MEK inhibitors for BRAF fusion-driven neoplasms.

Main Methods:

• Establishment and characterization of six melanoma cell lines harboring BRAF fusions.
• Assessment of cellular responses to various RAF and MEK inhibitors.
• Analysis of mitogen-activated protein kinase (MAPK) pathway activation.
• In vitro and in vivo efficacy studies of drug combinations.

Main Results:

• BRAF fusion-positive melanoma lines exhibited heterogeneous responses to RAF and MEK inhibitors.
• High expression levels of BRAF fusions correlated with resistance to inhibitors.
• Fusion partners with dimerization domains induced paradoxical MAPK pathway activation and hyperproliferation with first- and second-generation RAF inhibitors.
• Next-generation αC-IN/DFG-OUT RAF inhibitors effectively suppressed paradoxical activation.
• Combination therapy with next-generation RAF inhibitors and MEK inhibitors demonstrated enhanced efficacy in vitro and in vivo.

Conclusions:

• Specific features of BRAF fusion kinases determine therapeutic response to RAF inhibitors.
• Next-generation RAF inhibitors overcome resistance mechanisms associated with BRAF fusions.
• Combination of next-generation RAF and MEK inhibitors offers a promising therapeutic strategy for BRAF fusion-driven tumors.